ClinicalTrials.gg

Program

ixotatug vedotin

Also written as “TORL-1-23”, “TORL-1-23 and paclitaxel” and “TORL-1-23 and carboplatin”.

Its studies are mostly in Fallopian Tube Neoplasms · Ovarian Neoplasms · Carcinoma, Ovarian Epithelial, led by TORL Biotherapeutics.

Furthest: phase 2, since Nov 13, 20243 company-led studies, 3 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TORL Biotherapeutics33 open or runningphase 2since Nov 13, 2024Oct 21, 2021Oct 2027phase 2 · NCT06690775

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 21, 2021First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT05103683 · 90 planned · United States, South Korea
  2. Nov 13, 2024Phase 2 study in Carcinoma, Ovarian EpithelialNCT06690775 · 230 planned · United States, Australia, Austria and more
  3. Dec 17, 2025Phase 2 study in Fallopian Tube NeoplasmsNCT07322094 · 60 planned · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT06690775
  2. Dec 2027Primary completion: phase 2 study in Fallopian Tube NeoplasmsNCT07322094

TargetBeta

CLDN6 →read by rule
“An antibody-drug conjugate (ADC) composed of ixotatug, a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6), ”NCIt, by rule

Other programs on CLDN6

ProgramCompanyFurthest phaseStudies
CLDN6 RNA-LPX VaccineruleBioNTechphase 21
Anti-CLDN6/CD3 Bispecific Antibody XmAb541ruleXencorphase 12
Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455ruleBeOne Medicinesphase 11
Anti-Claudin 6 Antibody-drug Conjugate AT03-65ruleaxcynsis-therapeutics-pte-ltdphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07322094Fallopian Tube Neoplasms · United States2RecruitingDec 202760
NCT06690775Carcinoma, Ovarian Epithelial · United States, Australia, Austria and more2RecruitingOct 2027230
NCT05103683Ovarian Neoplasms · United States, South Korea1RecruitingAug 31, 202690

How it is read

Names in the registry

  • “TORL-1-23”, 4 entries
  • “TORL-1-23 and paclitaxel”, 1 entry
  • “TORL-1-23 and carboplatin”, 1 entry
  • “TORL-1-23, paclitaxel, and carboplatin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.